Abstract:Myelodysplastic Syndrome (MDS) represents a group of clonal hematopoietic disorders characterized by ineffective hematopoiesis and morphological dysplasia. Chromosomal instability is a prominent biological feature of MDS, with over 50% of patients with MDS harboring chromosomal abnormalities or complex karyotypes (CK). The mechanisms underlying mitotic and chromosomal defects associated with MDS remain elusive. In recent years, most studies have focused on the associations of TP53 mutation or deactivation with CK (Bernard et al, Nat Med 2020). Hitherto, besides TP53, few genes were reported associated with cytogenetic aberration in MDS (Bernard et al, Nat Med 2020). To fill this knowledge gap, RNA-Seq was conducted to find the CK-associated transcriptional factors and showed that ONECUT3 is significantly upregulated in MDS with CK, independent of TP53 mutation. Intriguingly ONECUT3 predicted poor survival of MDS patients. Our work indicates that ONECUT3 overexpression gave rise to multinucleated variants and complex karyotype in both TP53-KO MEF and TP53-WT MEF. Mechanistically, overexpressed ONECUT3 transcriptionally activated INCENP and CDCA8 through the direct binding to unique genomic regions, which was performed by RNA-seq and ChIP-seq concurrently. Upregulations of INCENP and CDCA8 induced the assembly of chromosome passenger complex (CPC) that were accumulated in addition to cell equator and midbody during the mitotic phases, consequently causing cytokinesis failure and defective chromosome segregation. As ONECUT3-OE cells attenuated chemo-sensitivity, we explored whether the compounds targeting the ONECUT3-CPC axis could alleviate chemoresistance. Homeobox domain was identified to function as the DNA binding by domain-deleted mutants and structural modeling (AlphaFold - DeepMind). One novel lead-compound C5484617 was later identified by protein structure-based drug virtual screening, to specifically target ONECUT3 and synergically re-sensitize the hypomethylating reagents in MDS with minimized cytotoxicity. In summary, the current study demonstrated that CK-associated TF ONECUT3 upregulates the CPC components in MDS, leading to mitotic defects and decreasing chemo-sensitivity. The Aurora B inhibitor (Barasertib) and a lead compound (C5484617) could help increase the sensitivity of MDS cells to HMA. Our findings are mechanistically significant and of great clinical relevance. The present investigation provides the foothold for further studies to identify novel approaches for MDS patients with limited therapeutic options. Moreover, our findings may be implemented for other cancer types, given that CK/genomic instability is a hallmark of cancer. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

SDF-1/CXCR4 signal is involved in decreased expression of p57kip2 in de novo MDS patients.

[Expression of P57kip2 in Patients with De Novo Myelodysplastic Syndrome and Its Relationship with SDF-1/CXCR4 Axis].

Reduced Response to Stromal Cell-Derived Factor-1(SDF-1) May Lead to Low Expression of P57kip2 in the Bone Marrow of Patients with De Novo Myelodysplastic Syndromes (MDS)

P57(Kip2) Expression is Related to Carcinogenesis and Tumor Progression in Laryngeal Tissues

Clinical Significance of Cytogenetic and Molecular Genetic Abnormalities in 634 Chinese Patients with Myelodysplastic Syndromes

Expressions of cell cycle related molecules in myelodysplastic syndrome

The Transcriptional Factor ONECUT3 is a Driver and Therapeutic Target for Complex Karyotype MDS

The Biological Behavior of SDF-1/CXCR4 in Patients with Myelodysplastic Syndrome

[Expression of Stromal Cell Derived Factor-1/Cxcr4 Biology Axis in Myelodysplastic Syndromes].

The Roles of SDF-1/CXCR4 Axis and Its Relationship with Apoptosis in the Myelodysplastic Syndromes.

Soluble PD-L1 as a novel biomarker predicts poor outcomes and disease progression in de novo myelodysplastic syndromes

High Co-Expression of PDCD1/TIGIT/CD47/KIR3DL2 in Bone Marrow is Associated with Poor Prognosis for Patients with Myelodysplastic Syndrome.

Ectopic expression of the transcription factor ONECUT3 drives a complex karyotype in myelodysplastic syndromes.

CDK Inhibitor P57 (kip2) is Negatively Regulated by COP9 Signalosome Subunit 6.

SDF-1/CXCR4 axis in myelodysplastic syndromes: correlation with angiogenesis and apoptosis.

Cytogenetic Response Based on Revised IPSS Cytogenetic Risk Stratification and Minimal Residual Disease Monitoring by FISH in MDS Patients Treated with Low-Dose Decitabine.

[Effects of Cyclin A1 on the Proliferation of SKM-1 Cells and Its Potential Role in Myelodysplastic Syndrome].

Expressions of Stromal Cell Derived Factor-1 and Its Receptor CXCR4 in Patients with Aplastic Anemia, Myeloid Dysplasia Syndrome and Acute Myelocytic Leukemia

Dlk1 Up Regulated Might Be an Important Event in Human MDS.

The effects of increased expression of DLK1 gene on the pathogenesis of myelodysplastic syndromes.

Differentiation and expression of membrane hemopoietic cytokine receptors on CD34+ bone marrow cells in patients with myelodysplastic syndromes